Calton & Associates’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$361K Sell
1,900
-3,329
-64% -$572K 0.05% 272
2026
Q1
$883K Sell
5,229
-106
-2% -$18.1K 0.13% 152
2025
Q4
$900K Sell
5,335
-169
-3% -$27.4K 0.13% 148
2025
Q3
$795K Buy
5,504
+81
+1% +$11.1K 0.12% 163
2025
Q2
$686K Sell
5,423
-82
-1% -$10.1K 0.12% 163
2025
Q1
$704K Sell
5,505
-111
-2% -$15.1K 0.16% 124
2024
Q4
$743K Buy
5,616
+3,034
+118% +$427K 0.33% 76
2024
Q3
$376K Sell
2,582
-3,255
-56% -$471K 0.14% 145
2024
Q2
$801K Sell
5,837
-429
-7% -$57.3K 0.4% 65
2024
Q1
$860K Sell
6,266
-398
-6% -$54.4K 0.42% 57
2023
Q4
$905K Buy
+6,664
New +$813K 0.36% 64
2023
Q3
Sell
-7,045
Closed -$894K 179
2023
Q2
$894K Sell
7,045
-83
-1% -$10.8K 0.42% 66
2023
Q1
$921K Sell
7,128
-316
-4% -$41.4K 0.43% 64
2022
Q4
$977K Buy
7,444
+3,694
+99% +$477K 0.38% 65
2022
Q3
$438K Buy
3,750
+2
+0.1% +$248 0.25% 99
2022
Q2
$440K Sell
3,748
-357
-9% -$42.4K 0.24% 106
2022
Q1
$534K Sell
4,105
-585
-12% -$76.2K 0.16% 154
2021
Q4
$715K Sell
4,690
-723
-13% -$112K 0.19% 135
2021
Q3
$875K Buy
5,413
+1,219
+29% +$205K 0.19% 131
2021
Q2
$687K Buy
4,194
+287
+7% +$44.2K 0.13% 163
2021
Q1
$588K Sell
3,907
-72
-2% -$11.4K 0.11% 169
2020
Q4
$603K Sell
3,979
-839
-17% -$120K 0.11% 156
2020
Q3
$652K Sell
4,818
-680
-12% -$92.3K 0.13% 129
2020
Q2
$752K Sell
5,498
-4,722
-46% -$602K 0.16% 105
2020
Q1
$1.1M Sell
10,220
-737
-7% -$84.9K 0.27% 69
2019
Q4
$1.32M Sell
10,957
-394
-3% -$44K 0.27% 72
2019
Q3
$1.13M Buy
11,351
+342
+3% +$35.8K 0.25% 74
2019
Q2
$1.2M Sell
11,009
-290
-3% -$30.8K 0.34% 53
2019
Q1
$1.26M Sell
11,299
-805
-7% -$88.3K 0.38% 50
2018
Q4
$1.17M Buy
12,104
+133
+1% +$14.1K 0.43% 49
2018
Q3
$1.46M Sell
11,971
-28
-0.2% -$3.3K 0.43% 38
2018
Q2
$1.41M Buy
11,999
+1,796
+18% +$192K 0.41% 41
2018
Q1
$1.09M Buy
10,203
+59
+0.6% +$6.54K 0.32% 66
2017
Q4
$1.18M Buy
+10,144
New +$1.08M 0.3% 57

Other funds holding IBB

Calton & Associates's IBB Position: Q2 2026 in Review

Calton & Associates reduced its iShares Biotechnology ETF (IBB) stake by 64% in Q2 2026, selling an estimated $572K and leaving 1,900 shares worth $361K. The position accounts for 0.05% of the portfolio, ranked #272.

Calton & Associates first reported a position in IBB in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.46M in Q3 2018. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Calton & Associates held 1,900 shares of iShares Biotechnology ETF worth $361K as of Q2 2026.
  • Calton & Associates sold 3,329 iShares Biotechnology ETF shares in Q2 2026, an estimated $572K.
  • iShares Biotechnology ETF made up 0.05% of Calton & Associates's portfolio in Q2 2026, its #272 holding.
  • Calton & Associates first reported a position in iShares Biotechnology ETF in Q4 2017 and has held it in 34 quarters since.
  • Calton & Associates's iShares Biotechnology ETF position peaked at $1.46M in Q3 2018.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Calton & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.